Subcutaneous nivolumab revolutionizes renal cell carcinoma care with faster, easier treatment

Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.

The biggest private biotech investments in May 2023

The companies ElevateBio, ReNAgade Therapeutics and Carmot Therapeutics bagged the biggest biotech investments in May 2023. Around the world, biomanufacturing and oncology players attracted the

June 5, 2023

bonyf R&D presents its two latest innovations at IDS 2025 in Cologne – Biotech Investments

bonyf NV / Key word(s): Product Launch/Market Launch bonyf R&D presents its two latest innovations at IDS 2025 in Cologne 30-Jan-2025 / 23:21 CET/CEST bonyf

February 1, 2025

TLDR – TDR News – March 7th to March 8th

Get a quick update on today’s essential news! We’ve condensed the most important information about Cannabis, Psychedelics, Crypto and Miners, AI, Small Cap REITS and

March 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.